A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Unione Sportiva Milanese was founded on 16 January 1902 as a multi-sports club, for compete in different disciplines, by Ambrogio Ferrario, Romolo Buni and Gilbert Marley at the Caffè Verdi in Porta Nuova in Milan. In the spring of 1904 the football section was established on the initiative of some footballers and gymnasts who left first A.C. Milan and then Mediolanum (among of which Umberto Meazza), while the affiliation to the Italian Football Federation (FIF), the current FIGC, took place in 1905. The shirt was black and white checked, with white shorts and black socks. Red and white were the colors of the second jersey. By virtue of this choice, against the current compared to the norm of the others teams, were nicknamed "Gli Scacchi" (the chessmen). At the end of the 1927-1928 championship, U.S. Milanese was automatically promoted to the National Division but was also forced by the fascist regime to merge with the Internazionale in the new Società Sportiva Ambrosiana, whose management was appointed Ernesto Torrusio, president of U.S. Milanese at the time, in favor of the fact that the registration number used to register for the championship was precisely that of U.S. Milanese. For two years the S.S. Ambrosiana celebrated the U.S. Milanese using its historic logo and the black and white checkered collar: S.S. Ambrosiana won the Italian football championship in 1929/30 season. 1932 saw the end of the merger with Internazionale and the reconstitution of U.S. Milanese, which was reborn only as a sports club without the football section. In 1945 U.S.
== Other animals == In fish, there is a single membrane known as the primitive meninx. Amphibians and reptiles have two meninges, and birds and mammals have three. Mammals (as higher vertebrates) retain the dura mater, and the secondary meninx divides into the arachnoid and pia mater.
=== Polymers === Already the first work on vinylene carbonate describes its bulk polymerization a colorless polymer, which hydrolyzes to a water-soluble product. Subsequent publications suggest that the first authors produced only low molecular weight oligomers. The preparation of higher molecular weight polymers with useful properties depends critically on the purity of the vinylene carbonate monomer. Vinylene carbonate can be homopolymerized in bulk, in solution, in suspension and in dispersion using radical initiators such as azobis(isobutyronitrile) (AIBN) or benzoyl peroxide. It can also be copolymerized with other vinyl monomers such as vinyl pyrrolidone or vinyl propionate.
=== 2013–2015: Emergence as a half-back flanker === The 2013 season saw Hibberd play every match of the year for the first time in his career. His performances during the season was described by The Age journalist, Rohan Connolly, as "the best football of his career" and he was named in Connolly's mid-season All-Australian team. His running off of half-back saw him compared to six time All-Australian, Corey Enright, by Rohan Connolly. After the announcement of the forty man squad for the 2013 All-Australian team, he was considered unlucky to miss out on selection by AFL Media journalist, Nick Bowen, and The Age journalist and former player, Matthew Lloyd. His improved season saw him finish fourth in the clubs best and fairest count. Despite a hamstring injury during the 2014 NAB Challenge, Hibberd played the first fourteen matches of the year, before he was forced to miss the round sixteen match against Port Adelaide at the Adelaide Oval due to an ankle injury. He returned to the side two weeks later for the seven point win against the Western Bulldogs at Etihad Stadium in round eighteen, before succumbing to a hamstring injury the next week and missed two weeks. He returned from injury in the three point win against West Coast at Etihad Stadium in round twenty-one, where he was named the best player for Essendon by The Age and AFL Media. He played the remainder of the season, including his first final in the twelve point loss against North Melbourne at the Melbourne Cricket Ground in the second elimination final.
Biko and several other black African NUSAS members were frustrated when it organised parties in white dormitories, which black Africans were forbidden to enter. In July 1967, a NUSAS conference was held at Rhodes University in Grahamstown; after the students arrived, they found that dormitory accommodation had been arranged for the white and Indian delegates but not the black Africans, who were told that they could sleep in a local church. Biko and other black African delegates walked out of the conference in anger. Biko later related that this event forced him to rethink his belief in the multi-racial approach to political activism:
Sources: en.wikipedia.org
== Adverse effects == Aminoglycosides can cause inner ear toxicity which can result in sensorineural hearing loss. The incidence of inner ear toxicity varies from 7 to 90%, depending on the types of antibiotics used, susceptibility of the patient to such antibiotics, and the duration of antibiotic administration. Another serious and disabling side effect of aminoglycoside use is vestibular ototoxicity. This leads to oscillopsia (gaze instability) and balance impairments that impact all aspects of an individual's antigravity function. This loss is permanent and can happen at any dose. Frequent use of aminoglycosides could result in kidney damage (acute kidney injury) that could lead to chronic kidney disease.
===== Herpes zoster (chickenpox and shingles) ===== Varicella zoster is the virus responsible for chickenpox and shingles (also known as herpes zoster). The CDC advises that breastfeeding is safe to continue as long as the breasts are clear of lesions, also emphasizing that if pumping or hand expressing milk, proper hand-hygiene should be used to minimize transfer.
In April 2007, Dein left Arsenal due to "irreconcilable differences" about the future of the club. Wenger described it as a "sad day for Arsenal," and sought assurances from the board over his future as well as reasons for Dein's departure. The instability at board level influenced club captain Henry's decision to leave Arsenal in June 2007, which led to uncertainty over Wenger's position. In September 2007, Wenger signed a new three-year extension, stating that he remained committed to "the club of my life." (In 2021, Wenger revealed that his signing of the contract extension was his side of a deal with the Arsenal board in the building of the new stadium, because he requested its construction.) Arsenal flourished in Henry's absence, with Emmanuel Adebayor, Mathieu Flamini and Fàbregas playing a more prominent role in the 2007–08 season. Defeat to Middlesbrough in December 2007 ended a run of 22 league matches unbeaten, but Arsenal soon built a five-point lead over Manchester United. A career-threatening injury to striker Eduardo against Birmingham City on 23 February 2008 acted as a turning point in Arsenal's season. Wenger, incensed at the aggressive tactics of opponents, called for a ban on tackler Martin Taylor in his post-match interview; he later retracted the comment. Arsenal's form subsequently suffered, and a run of three consecutive draws in March allowed Manchester United and Chelsea to overhaul them as they finished the season in third. Arsenal made a troubled start to Wenger's twelfth season.
=== Pakistan === On 8 April, amidst the deadline set by Trump, Pakistani Prime Minister Shehbaz Sharif called on Trump to extend his deadline for Iran to reopen the Strait of Hormuz by two weeks. It was also reported by CBS, quoting Pakistani sources, that a ceasefire with Iran was being negotiated by Sharif. Later that day, Prime Minister Sharif announced on social media that "...Islamic Republic of Iran and the United States of America, along with their allies, have agreed to an immediate ceasefire everywhere including Lebanon and elsewhere, EFFECTIVE IMMEDIATELY..." while also lauding both parties for their diplomacy. In a 10 April social media post, Pakistani Defense Minister Khawaja Asif called Israel "evil and a curse for humanity" while accusing Israel of genocide against Lebanon. The Israeli Prime Minister's Office responded, "This is not a statement that can be tolerated from any government, especially not from one that claims to be a neutral arbiter for peace". Asif later deleted the post.
The brown bear has a hump between its shoulders, a distinction from other bear species. This hump is formed by large muscles, allowing for a wide range of motion, which the bear mainly uses to put pressure on the soil as it digs for food. The bison also has a hump between its shoulders, made almost entirely of muscle and supported by long skeletal spines. The bison hump's purpose is to hold up the animal's large head, and also enables the animal to use its head as a snow shovel in the winter, swinging it side to side with its hump muscles. Such foraging behavior sets the bison apart from other ungulates, which typically use their feet to scrape away snow. Moose, similarly, have a shoulder hump of muscle that is necessary to hold up their large head and, in males, antlers.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.